PERCUTANEOUS BIOPSY IN ONCOLOGICAL PATHOLOGY OF THE SPINAL COLUMN by Rusu, Tatiana
REvIEw ARTIClES Curierul medical, February 2016, Vol. 59, No 1
Percutaneous biopsy in oncological pathology of the spinal column
T. Rusu
Department of Spinal Neurosurgery, Institute of Neurology and Neurosurgery, Chisinau, the Republic of Moldova
Corresponding author: tatianarussu@mail.ru.  Received December 28, 2015; accepted February 05, 2016
Abstract
Background: Among oncological patients there is a group of patients with outcomes hard to predict because of few possibilities to diagnose, even though 
there are a lot of procedures, some of them being very painful. Absence of a diagnose lowers the chances of healing even before treatment starts, fact that 
makes patients refuse specific therapy. Often, these patients are referred to different medical centers during the short life that they have left. We are talking 
about patients in whom the clinical signs are metastasis; meanwhile the primary tumor doesn’t have any manifestations at all.  Percutaneous biopsy of 
the spinal column is a minimal invasive and rapid technique that obtains tissue samples from the vertebral body, intradiscal regions and paravertebral 
regions. Despite progress of computed tomography and magnetic resonance imaging technologies, basic diagnosis of different pathologies of the spinal 
column remains difficult. In most of the cases, a tissue sample is needed to settle a clear diagnosis. Percutaneous biopsy is preferred over the open biopsy 
because of the low costs, morbidity and mortality. The aim of this article is to review and to highlight in details the efficiency of percutaneous biopsy, by 
pointing out its influence on the treatment and decisions in such branches like surgery, chemotherapy, radiotherapy depending on the morphological 
nature of the lesions.
Conclusions: Percutaneous biopsy of the spinal column is the elective procedure in definitive diagnosis of pathological lesions. 
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Introduction
Among oncological patients there is a group of patients 
with outcomes hard to predict because of few possibilities to 
diagnose, even though there are a lot of procedures, some 
of them being very painful. Absence of a diagnose lowers 
the chances of healing even before treatment starts, fact that 
makes patients refuse specific therapy. Often, these patients 
are referred to different medical centers during the short life 
that they have left. We are talking about patients in whom the 
clinical signs are metastasis; meanwhile the primary tumor 
doesn’t have any manifestations at all [1].
 Studies made on patients with metastasis without a 
known primary tumor, show that, until now, there is no 
optimal algorithm for diagnosing patients with metastasis 
with unknown primary tumor, an adequate determination of 
different methods of diagnosis and evaluation of metastasis 
does not exist [1].
 Studies of autopsies with bone metastasis have 27% in-
cidence in patients with carcinomas, 47-85% of whom die of 
breast cancer, 33-85% – of prostate cancer and 32-60% – of 
lung cancer. Bone metastasis may be the first clinical mani-
festation in almost 20% of patients with systemic cancer [57].
 Global incidence of bone metastasis in patients with all 
kinds of cancer is about 70%. After lungs and liver, bones 
are on the 3rd place of metastasis. Out of all metastasis of the 
spinal column, 3% are primary unknown, and 75% derive 
from secondary tumors. About 30% of patients with cancer 
have metastasis at the moment of diagnose [63].
 Metastases appear in a way that does not follow the laws 
of typical dissemination of tumors with known localization 
[1].  D. A. Casciato [25] compared the group of patients with 
metastasis with unknown primary tumor (later the primary 
tumor was found), with the group of patients with unknown 
source of the primary tumor and discovered the following 
particularities: patients with lung cancer had bone metastasis 
in 30-50% of the cases, and patients that had metastasis with 
an unknown focus (which later was found in the lungs), had 
bone metastasis only in 5% of the cases. In a similar way, bone 
metastases were found in 5-10% of patients with pancreatic 
cancer, and patients with metastasis with an unknown focus 
(which was later found in the pancreas) represented 30% of 
the cases. Metastases in the lungs and liver are found in 15% 
of patients with prostate cancer; meanwhile patients with 
metastasis with unknown focus (later discovered in the pros-
tate), represent 50% of the cases of lung and liver metastasis. 
Atypical dissemination of tumors prevents essentially the 
process of identification of the primary focus, which in most 
of the cases complicates the localization’s prognosis (according 
to the identified metastasis) [25].
 It was established that during a thorough examination, 
that includes all methods of diagnosis, the primary focus could 
be identified in only 7.1% of the patients [43, 66]. Costs of 
examination of such a patient in USA are about 18.000 USD. 
The mean life expectancy of these patients does not exceed 
8.1 months [62, 68].
 Choosing a correct treatment tactics for spinal metastasis 
is difficult and depends on many factors, primary the life ex-
pectancy and the balance between the surgery risks against the 
risk of quality of life improvement. Prognosis was designed to 
help the clinician to decide the optimal tactics, but until now, 
we are against the version of choosing the best option, that in 
most of the cases is based on the subjective experience of the 
surgeon as well [22]. Generally, it is admitted that a surgery 
is indicated when a patient has a life expectancy more than 3 
months [53].
 Out of all oncologic patients without apparent clinical me-
tastasis, only 50% can be cured with loco-regional treatments 
(surgery, radio-surgery), and according to recent data, about 
60% of patients have microscopic metastasis at the moment 
of diagnosis. Metastases are responsible for almost 90% of 
deaths from cancer. About 5-30% of patients with metastasis 
in the spinal column have neurological symptoms. Metastasis 
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represents the fundamental process that differentiates the 
benign and malignant tumors, that transforms an organ cancer 
in a disease of the entire body, systemic disease [22, 52], and 
these patients become patients of a multi-modal branch [12, 
31, 58, 59, 146]. Prognosis for patients with metastasis in the 
spinal column is the most important factor in choosing the 
correct tactics of treatment [16, 26]. 
 The key to success in deciding the tactics of treatment 
of tumors of the spinal column is the histological type of the 
tumor. Tissue biopsy represents the basis of oncology.
Biopsy can be of three types:
- Percutaneous (transpedicular, transfacetar, lateral ap-
proaches);
- Open incision (when a larger quantity of tissue is re-
quired);
- Excisional.
 Before imagistic guidance techniques of spinal column 
biopsy were developed, open biopsy procedure was necessary 
for definitive diagnosis. The advantage of open biopsy was do-
uble: the first was direct visualization, big and multiple tissue 
samples can be obtained for histological examination; and the 
second was the possibility of spine surgical decompression 
and / or column stabilization. 
 Percutaneous biopsy of the spinal column was firstly 
described by Minge in 1934 and then by Robertson and Ball 
in 1935 [56]. Though, their procedure did not use imagistic 
guidance. Siffert and Arkin [60] used posterior-lateral approa-
ch for spinal biopsy with radiographic guidance. Biopsy with 
imagistic guidance was reported in literature in 1949 with 
conventional radiography, followed by fluoroscopy in 1969, 
computed tomography (CT) in 1981, magnetic resonance ima-
ging (MRI) in 1986, and CT fluoroscopy in 1996 [56]. At the 
beginning, open biopsies were performed, but percutaneous 
biopsy proved to be a more rapid, cost effective method with 
less complications [2, 3, 6, 17, 54].
 There are 5 major indications for percutaneous biopsy of 
spinal lesions:
1. In order to identify an unknown lesion before a treat-
ment plan is established;
2. Lesion that does not respond to empirical conventional 
treatment;
3. Infection that does not respond to 6-week treatment;
4. Fracture from compression on an unknown focus;
5. Intensification or persistence of pain in a patient with 
history of Paget disease [46].
Additional indications are:
- Metastasis confirmation in case of known primary focus;
- Diagnosis of primary bone lesion;
- Specific of nonspecific infection, with antibiotic sensibil-
ity;
- Determination of chemotherapy efficiency;
- Multiple myeloma cytological diagnosis;
- Benign lesion confirmation (osteoporosis, renal dystro-
phy);
- Diagnosis confirmation through histology and immune-
histochemical methods in cases of FFD tumors;
- Symptomatic synovial cysts.
The major indication of this method is the correct choice 
of subsequent management of oncological patients, important 
in case of multimodal treatment’s tactic change in this category 
of patients [4].
Among the first indications for biopsy are the lithic or 
blastic lesions, soft expansive process in the spinal column 
in patients with oncological history [5, 6, 61].
The second place after metastasis are discitis, with adequa-
te planning of management of the symptomatic treatment, 
surgical radicalness, prevention of infection progress to sepsis, 
of local progression of the infection in cases of metallic im-
plants [6, 7, 8], followed by pathological fractures, aspiration 
of symptomatic synovial cyst, etc [6, 9, 10].
Relative contraindications are:
- Hemorrhagic diathesis, coagulopathies, thrombocyto-
penia (50.000);
- Infection, including infection at the level of projection of 
the biopsy, including adjacent infection of the affected 
vertebrae;
- Non-accessible localization, for example C1 arch, the 
tooth of C2, bone fusion;
- Uncritical patient, with the need of general anesthesia;
- Pregnancy;
- Allergy to medications required for the procedure;
- Patients with medullar compressions at the level of 
interest [10, 11].
An absolute contraindication for percutaneous biopsy is 
coagulopathy. Nevertheless, even this condition, if correctly 
managed in advance, can be sufficiently corrected in order to 
permit the surgeon to make the procedure. If a vascular tumor, 
such as renal metastasis, is suspected, angiography should be 
taken into consideration in preliminary diagnostics.
Imagistic methods of intra-operatory guidance are:
Ultrasonography. Offers real time monitoring, it is rapid, 
cheap, avoids radiation and offers the possibility to visualize 
the tip of the needle during the entire procedure. It is often 
used in diagnostics of parenchymal organs such as: liver, thy-
roid gland, pancreas, lungs, prostate, breast. Its applicability 
at the level of spinal column resumes to superficial lesions of 
cervical spine [12, 13].
Fluoroscopy. The first fluoroscopic procedure was made 
in 1949, followed by single plan, bi-plan and C-arm fluoro-
scopy [14, 15].
Studies about fluoroscopic guidance and CT uncover the 
advantages and disadvantages of each procedure [46, 54, 56, 
65].
Computed tomography (CT) has been used more than 
20 years. It is a standard for many institutions. CT offers an 
exact trajectory planning, avoids lung passage at the thoracic 
level or other vital organs, it also offers to delimitate solid, 
necrotic, sclerotic lesions and exact depth. The disadvantage 
is the duration of the procedure and the dose of radiation for 
the patients and medical staff, and cost as well [18, 19].
CT fluoroscopy was described for the first time in 1994 
[19, 21], it combines the advantages of conventional fluoro-
scopy with real-time visualization of six concomitant images. 
CTF is useful for visualization of retro-peritoneal organs that 
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are prone to physiological movements. One of the major con-
cerns about CTF is the great dose of radiation. Conventional 
fluoroscopy doses are measured in centigrays per minute 
of exposure, meanwhile, the doses of CTF are measured in 
centigrays per second of exposure [19, 21].
Magnetic resonance imaging is a unique method, but 
with many economical disadvantages, described in literature 
being 15% more expensive than other methods [23, 24]. First 
of all, the procedure is expensive, the instruments must be 
made of titanium, the duration of the procedure is increased, 
also patients must not have contraindications for this type of 
procedure [23].
Before the procedure, patients must be fully examined 
clinically and paraclinically as for a surgical intervention: 
complaints, history, oncological history, and contact with 
contagious diseases. If the patient takes aspirin or other NSAI 
drugs, they must be suspended 3 days prior the procedure, 
with renewal after the procedure; in case of infection suspect, 
suspention of antibiotics 48h prior the procedure, special 
attention is paid to anesthetics drugs [25, 27, 29].
The procedure is made in the operating room, under 
sterile conditions, or in an angiographic laboratory, with a 
specialized table, that allows C-arm rotations for rapid anterior 
and profile images. The positioning of the patient on the table 
depends on the affected region, for superior cervical region 
with trans-oral and oropharyngeal approach the position is 
dorsal, in the rest of the cases, the position is ventral. Indica-
tions for posterolateral or transpedicular approach depend on 
the localization of the lesion. If the lesion is located primarily 
in the intervertebral space, or in cases of infectious diseases, 
posterolateral approach is to be used. This approach is man-
datory in cases of lesions in the inferior part of the vertebral 
body. However, if the lesion is situated in the posterior part of 
the vertebral body, or if the pedicle is implied, transpedicular 
method is very efficient for biopsy [55, 64]. In cases of lesions 
of the entire vertebral body, transpedicular approach is usually 
preferred [10. 36, 45, 50, 54].
Skin is treated in a standard way, 3 times, with antiseptics. 
The marking of the entrance point is made with the C-arm 
(necessary angle inclusive, which can be estimated based on 
CT). Skin incision is about 2-3mm, with local anesthesia made 
with 1% lidocaine infiltration through the pedicle. Under 
fluoroscopic guidance advancing through the pedicle is made 
in case of transpedicular approach, or lateralized in case of 
costotransverse approach. Biopsy material is taken from seve-
ral superficial and profound regions, soft paravertebral tissue 
inclusive, if required, aspirational liquid is taken for cytologic, 
bacteriologic exam [30].
Taken material is being taken for necessary examinations: 
histological, cytological, immune histological or bacteriolo-
gical if required.  Schematically surgical approaches (fig. 1).
Histology is the tissue examination sampled from the 
patient.  Cyto-pathology is the cell study obtained from the 
tissue by means of fine needle biopsy.  Benign and malignant 
tumors have two basic components:
1. Neoplastic and proliferative cells – their parenchyma;
2. Supporting stroma made of connective tissue and blood 
vessels.
Fig. 1.  Approaches in percutaneous biopsy of spine.
The parenchyma is the proliferative compartment of 
tumors and as a result determines the pathological compart-
ment, tumoral growth and evolution that critically depends 
on its stroma [52].
Hyperplasia represents the physiological excessive proli-
feration of cells (pregnancy, breast-feeding, physical effort), 
compensatory proliferation (wounds, bone fractures, healing 
processes) and pathological (if the excess goes beyond the 
physical capacities). Tumoral growth doesn’t obey any of 
these rules, neoplastic modifications can occur in hyperplastic 
tissues.
Dysplasia is a size, shape and cell organization disturbance 
in a tissue, as a result of growth and differentiation disrupti-
on caused by irritative factors, inflammation and hormonal 
factors/
Dysplasia is abnormal, but does not equal to malignancy 
[52].
Differentiation is about the functional and morphological 
features neoplastic cells resemble the normal cells; the absence 
of differentiation is called anaplasia [52].
Absence of differentiation or anaplasia is marked by a 
number of morphological modifications:
- Pleomorphic;
- Altered nuclear;
- Mitosis [28, 52].
There are national guidelines and standard protocols for 
pathological analysis of the majority of tumors. A vast number 
of staining can be made besides the standard staining with 
hematoxylin-eosine. Important progress of the techniques 
made it possible to offer results in an hour or one day. Immune 
histochemistry and molecular pathology are used in order to 
classify tumors [52]. 
The goal of immune histochemistry is to detect cellular 
or tissue-specific antigens by means of marked antibodies 
that can be visualized through microscopy of fluorescence. 
Immune histochemistry is very important in stabilizing the 
differentiation line in poorly differentiated tumors. The ma-
jority of pathologists use an approach based on steps. On the 
first step, they use generic markers that contain cytokeratins 
(for epithelial differentiation), melanocytic markers, CD 45 
(leucocyte common marker, for hematopoietic differentiation) 
and vimentine (for mesenchymal differentiation). On the 
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second step, attention is paid to specific antibodies selected 
based on previous results [52].
Advantages of cytopathology:
- Small tissue lesions;
- Lesions that are not accessible for large biopsy;
- Patients’ comfort;
- Rapid diagnosis.
Disadvantages of cytopathology:
- Limited possibility of detailed classification;
- Not capable to differentiate cancer.
Criteria that confirm diagnosis or at least suspect the 
diagnosis are:
1. Morphology of the cancer cell is different (size, shape) 
compared to the normal cell.
2. The nucleus of the cancer cell is bigger and is hyper-
chromatic than the normal cell, nuclei-cytoplasm ratio 
is bigger, nucleoluses are larger.
3. The number of cells in mitosis is greater in cancer cells, 
more than 20 mitosis per 1000 cells (1 in 1000 cells).
4. Abnormal mitosis, “giant cells”, with polymorph features 
or multiple nuclei.
5. Normal tissue invasion of a neoplasm with high pos-
sibilities of metastasis [20]. 
Some authors claim that biopsy tissue with intra-opera-
tory cytology had 96.9% sensibility, 100% specificity, 100% 
positive predictive value, negative predictive value of 87.5% 
well-correlated with the histological examination with 95.7% 
precision. The mean needed for result declaration was 8.9 
+/- 1.7 minutes [38].
Complications in case of percutaneous biopsy of the spinal 
column are estimated to be less than 1% [31, 32].
Complications associated with percutaneous biopsy of the 
spinal column are:
1. Active bleeding;
2. Hematoma;
3. Vascular lesion;
4. Dural or radicular lesions (of the spine or nerves) with 
transitory or permanent neurological deficit.
5. Pneumothorax;
6. Infection, meningitis inclusive. 
Most of the complications occur in the thoracic part of the 
spinal column: pleura / lung lesions, lesions of main vessels 
[33, 34], pneumothorax, radicular or medullar lesions with 
transitory neurologic deficit. Allergic reactions, even anaphy-
lactic shock, are possible [35]. Post-procedure pain usually 
recedes after 24h. Hemorrhagic and infectious complications 
occur rarely.
 Percutaneous biopsy of the spinal column is a well-
known, efficient, rapid and less invasive technique that obtains 
tissue samples from the vertebral body, intradiscal regions and 
paravertebral regions [6, 10, 21, 24, 30, 36]. Despite progres-
ses of CT and MRI technologies, basic diagnosis of different 
pathologies of the spinal column remains difficult. In most of 
the cases, a tissue sample is needed to settle a clear diagnosis. 
Percutaneous biopsy is preferred over the open biopsy because 
of the low costs, morbidity and mortality [6].
 Efficiency of percutaneous biopsy in the management 
of spinal lesions was largely evaluated [10, 67]. The risk im-
plied in percutaneous biopsy was estimated differently: 0% 
[44]. 2.2% [55], 7.6% [10] and 26% [29]. The most frequent 
complications reported were pulmonary, neurological and 
infectious complications. Precision of vertebral biopsy with 
posterolateral approach ranged between 50% and 90% [10, 
29, 44, 45, 55, 67]. Other authors claim that the precision rate 
of percutaneous biopsy is 87-95%, and complications’ rate is 
0.2% [54].
 Biopsy results which affect subsequent clinical mana-
gement of the patient and will influence the treatment and 
decisions in such branches as surgery, chemotherapy, radio-
therapy, antibiotic therapy depending on the morphological 
nature of the lesions.
 Patients’ survival with metastasis in the spinal column 
according to the morphology of the primary focus of the 
tumor (tab. 1).
 Table 1
Patients’ survival with metastasis in the spinal column
Type of cancer Mean survival 5 years % Mentions
Breast cancer 1-2 months 13%
Prostate cancer 1-2 months 17%
Lung cancer 3 months 2%
Multiple mieloma 2-3 years
Colo-rectal cancer 13 months
Cervical cancer The majority die in 18 months
Kidney cancer 1 year
30% if there 
is a single 
bone tumor 
Precision of percutaneous biopsy with different imagistic 
guidance methods is estimated in literature to be 88-100% 
[1, 37, 39, 40].
 Positive prediction value of this procedure is 82%, nega-
tive prediction value is 100% [41]. Precision rate is higher in 
cases of metastasis or recurrent sarcoma, being 94% [41, 42, 
44, 45, 47]. Capacity of culturing in cases of infection is low, 
ranging from 46% to 91% [48, 49, 50].
Conclusions
Percutaneous biopsy of the spinal column is a safe proce-
dure, efficient and cost effective. It is the elective procedure 
in definitive diagnosis of pathological lesions of the spinal 
column.
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